Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | PGD | P52209 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159295 | 0.81 | PDE4A (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL5790915 | 0.81 | PDE4A (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL5792045 | 0.81 | PDE4A (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL671072 | 0.81 | PDE4A (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL669339 | 0.81 | PDE4A (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL185904 | 0.81 | PDE4A (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL5042 | 0.81 | PDE4A (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL5792603 | 0.81 | PDE4A (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL5788771 | 0.81 | PDE4A (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL5791149 | 0.81 | PDE4A (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | INTERSTITIAL THERAPEUTICS (CH) | 2009-12-31 | — | — | US | claimed |
| EP-1789030-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| EP-1789107-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| WO-2006024488-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024490-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024492-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| EP-3399026-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20210189348-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE | 2021-06-24 | — | — | US | disclosed |
| WO-2021040999-A1 | METHODS AND COMPOSITIONS FOR STIMULATING EXOSOME SECRETION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-03-04 | — | — | WO | disclosed |
| US-10934528-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-02 | — | — | US | disclosed |
| US-10308912-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3399026-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | The Scripps Research Institute (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-2580320-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20070292478-A1 | Medical Implant Provided with Inhibitors of Atp Synthesis | INTERSTITIAL THERAPEUTICS (CH) | 2007-12-20 | — | — | US | disclosed |
| EP-1789030-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | disclosed |
| EP-1789107-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006024488-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024490-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024491-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024492-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | ATP5ME, ATP5F1A, ATP5MG | LMNA 4786/4885L3MBTL1 3926/4885PDE4A 1330/4885 |
| US-20070292478-A1 | Medical Implant Provided with Inhibitors of Atp Synthesis | ATP5F1A, ATP5ME, ATP5MG | LMNA 4294/4885L3MBTL1 4267/4885PDE4A 651/4885 |
| US-10934528-B2 | Reprogramming of cells to a new fate | ALPG, POU5F1, POU2F1 | LMNA 1313/4885L3MBTL1 306/4885PDE4A 2015/4885 |
| US-20210189348-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | ALPG, POU5F1, POU2F1 | LMNA 1313/4885L3MBTL1 306/4885PDE4A 2015/4885 |
| US-10308912-B2 | Reprogramming of cells to a new fate | ALPG, POU5F1, POU2F1 | LMNA 1313/4885L3MBTL1 306/4885PDE4A 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.